Allergan Third-Quarter Profit Tops Estimates as Sales Climb

Updated on
  • Revenue from top drugs Botox, Namenda is short of estimates
  • Company doesn't expand on previous comments on Pfizer deal

Allergan Plc, Pfizer Inc.’s target in a deal that could be the largest health-care acquisition of all time, reported third-quarter earnings that topped analysts’ estimates as the company’s recent takeovers added to revenue.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.